Relevant bibliographies by topics / Sunitinib treatment

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'Sunitinib treatment'

Author: Grafiati
Published: 28 May 2022
Last updated: 30 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Sunitinib treatment.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Sunitinib treatment"

1

Kanaan, Ziad, Zain Kulairi, Mirela Titianu, Sandip Saha, and Sarwan Kumar. "Guillain-Barré Syndrome following Treatment with Sunitinib Malate." Case Reports in Oncological Medicine 2014 (2014): 1–2. http://dx.doi.org/10.1155/2014/712040.

Full text
Abstract:
Sunitinib malate (Sutent, SU011248) is an oral multitargeted tyrosine kinase inhibitor (TKI) used for the treatment of metastatic renal cell carcinoma and imatinib (Gleevec)—resistant gastrointestinal stromal tumor (GIST) with few reported side effects including asthenia, myelosuppression, diarrhea, and mucositis. Scarce literature exists regarding the rare but often serious toxicities of sunitinib. Autoimmune and neurological side effects have been linked to sunitinib’s inhibition of VEGF receptors with a corresponding increase in VEGF levels, which is associated with development of different
APA, Harvard, Vancouver, ISO, and other styles
2

Park, Seongjoon, Jae-Lyun Lee, Inkeun Park, et al. "Comparative efficacy of sunitinib versus sorafenib as the first-line treatment for patients with metastatic renal cell carcinoma." Journal of Clinical Oncology 30, no. 15_suppl (2012): e15080-e15080. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e15080.

Full text
Abstract:
e15080 Background: Currently, sunitinib has been recommended as the primary treatment in the patients with metastatic renal cell carcinoma (mRCC) among the vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI). However, there are no published clinical data that compared directly the efficacy of targeted agents in the first line setting, and first-line treatment in mRCC patients is yet to be determined. Methods: To compare the efficacy and toxicities between sorafenib and sunitinb, clinical database was used to identify all patients with mRCC treated with VEGF TKIs in Asan Med
APA, Harvard, Vancouver, ISO, and other styles
3

Cardona, Andrés Felipe, Javier Godoy, Heidy Cáceres, et al. "First line treatment for metastatic renal cell carcinoma in Colombia : a cost-effectiveness analysis." Revista Colombiana de Hematología y Oncología 1, no. 3 (2012): 15–23. http://dx.doi.org/10.51643/22562915.310.

Full text
Abstract:
Objective: To perform a local study based on an economic evaluation of first-line treatment of metastatic renal cell carcinoma in Colombia, since 2006-2007. Methods: We developed a Markov model using 6-week cycles to evaluate the cost-effectiveness of 4 interventions (IFN, sunitinib, bevacizumab + IFN, sorafenib) used as standard first-line treatment for mRCC in Colombia. The model used the thirdparty payer perspective and a 10-year time-line with all patients continuing with active treatment until progression, when it became acceptable to proceed to a second-line treatment or best supportive
APA, Harvard, Vancouver, ISO, and other styles
4

Baldazzi, Valentina, Renato Tassi, Alberto Lapini, Marco Carini, and Roberto Mazzanti. "Newly onset hyperlipidemia in metastatic renal cell carcinoma patients treated with sunitinib." Journal of Clinical Oncology 30, no. 5_suppl (2012): 459. http://dx.doi.org/10.1200/jco.2012.30.5_suppl.459.

Full text
Abstract:
459 Background: To our knowledge effects of sunitinib on serum lipids metabolism are not described. Here we report about the occurrence of hypercholesterolemia and hypertriglyceridemia in patients receiving sunitinib for metastatic renal cell carcinoma (mRCC). Methods: Between July 2008 and September 2011, we prospectively evaluated serum triglycerides and cholesterol in 37 patients receiving sunitinib for mRCC according to classic 6-week schedule. On average they received sunitinib for 10.3 cycles. Serum lipids were measured before the beginning of treatment and at the end of each sunitinib O
APA, Harvard, Vancouver, ISO, and other styles
5

Han, Mi-Ran, Kyu-Yun Jang, and So-Yeon Jeon. "Sunitinib and TB lymphadenitis: An unexpected link in oncological therapy: a case report." Medicine 104, no. 29 (2025): e43158. https://doi.org/10.1097/md.0000000000043158.

Full text
Abstract:
Rationale: Gastrointestinal stromal tumors (GIST) are neoplasms that originate from the interstitial cells of cajal located in the muscular layer of the gastrointestinal tract. Surgery is the primary treatment options; however, if resection is not feasible, or in cases of metastatic or recurrent GIST, systemic chemotherapy can be considered as an alternative. Sunitinib, a multi-targeted tyrosine kinase inhibitor, is indicated as an essential second-line treatment for GIST following disease progression or intolerance to imatinib mesylate. It works by slowing down or stopping the growth of tumor
APA, Harvard, Vancouver, ISO, and other styles
6

Ferrari, Silvia Martina, Marco Centanni, Camilla Virili, et al. "Sunitinib in the Treatment of Thyroid Cancer." Current Medicinal Chemistry 26, no. 6 (2019): 963–72. http://dx.doi.org/10.2174/0929867324666171006165942.

Full text
Abstract:
Background: Sunitinib (SU11248) is an oral multi-target tyrosine kinase inhibitor (TKI) with low molecular weight, that inhibits platelet-derived growth factor receptors (PDGF-Rs) and vascular endothelial growth factor receptors (VEGFRs), c-KIT, fms-related tyrosine kinase 3 (FLT3) and RET. The concurrent inhibition of these pathways reduces tumor vascularization and causes cancer cell apoptosis, inducing a tumor shrinkage. Sunitinib is approved for the treatment of imatinib-resistant gastrointestinal stromal tumor (GIST), renal carcinoma, and pancreatic neuroendocrine tumors. Methods: We sear
APA, Harvard, Vancouver, ISO, and other styles
7

Godoy, J., A. F. Cardona, H. Cáceres, et al. "Cost-effectiveness analysis of first-line treatment for metastatic renal cell carcinoma (mRCC) in Colombia (ONCOLGroup study)." Journal of Clinical Oncology 27, no. 15_suppl (2009): e16150-e16150. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.e16150.

Full text
Abstract:
e16150 Background: Renal cell carcinoma has increased its incidence by 126% since 1950. A local study developed a complete economic evaluation of sunitinib versus IFN in first-line treatment of mRCC in Colombia, finding that sunitinib was more cost-useful and cost-effective. Methods: A Markov model was developed using 6-week cycles for evaluating the cost-effectiveness of four interventions (IFN, sunitinib, bevacizumab+IFN, sorafenib) approved as first-line treatment for mRCC in Colombia. The model used the third-party payer perspective and a 5-year time-line; it also presumed that all the pat
APA, Harvard, Vancouver, ISO, and other styles
8

Nurhasni, K. A. R. Ku, J. Sabirin, S. E. Wan Puteh, and M. Dahlui. "An Economic Evaluation of Sunitinib Versus Pazopanib As First Line Treatment of Metastatic Renal Cell Carcinoma." Journal of Global Oncology 4, Supplement 2 (2018): 72s. http://dx.doi.org/10.1200/jgo.18.13100.

Full text
Abstract:
Background: Sunitinib and pazopanib have been shown to benefit the metastatic renal cell carcinoma patients as evidence suggested that these treatments have a comparable clinical effectiveness. However, no local economic evaluation was known to determine the value of these treatments in Malaysia. Aim: To estimate the financial implication of sunitinib and pazopanib as first line treatment of metastatic renal cell carcinoma in Malaysia by conducting a cost minimization analysis. Methods: A state transition model was developed using Microsoft Excel® 2010 with a hypothetical cohort modeled over 1
APA, Harvard, Vancouver, ISO, and other styles
9

Bresciani, Giulia, Angeliki Ditsiou, Chiara Cilibrasi, et al. "EGF and IGF1 affect sunitinib activity in BP-NEN: new putative targets beyond VEGFR?" Endocrine Connections 8, no. 6 (2019): 680–90. http://dx.doi.org/10.1530/ec-19-0192.

Full text
Abstract:
Broncho-pulmonary neuroendocrine neoplasms (BP-NENs) are neoplasms orphan of an efficient therapy. Available medical treatments derived from clinical trials are not specific for the management of this malignancy. Sunitinib is a multi-receptor tyrosine-kinases (RTKs) inhibitor that has already shown its efficacy in NENs, but there are no available data about its action in BP-NENs. Therefore, our aim was to understand the effects of RTKs inhibition promoted by sunitinib in order to evaluate new putative targets useful in malignancy treatment. Since our results underlined a role for EGFR and IGF1
APA, Harvard, Vancouver, ISO, and other styles
10

Rizzo, Mimma, and Camillo Porta. "Sunitinib in the treatment of renal cell carcinoma: an update on recent evidence." Therapeutic Advances in Urology 9, no. 8 (2017): 195–207. http://dx.doi.org/10.1177/1756287217713902.

Full text
Abstract:
Sunitinib is a multitarget tyrosine kinase inhibitor endowed mainly by antiangiogenic effects, although an indirect inhibitory effect on tumor growth and, more recently, a complex activity on antitumor immune response has been described. From approval by the US Food and Drug Administration (FDA) in January 2006, sunitinib represents a key molecule in the treatment of metastatic renal cell carcinoma (mRCC) due to the peculiar molecular pathogenesis of this neoplasm. Over the past 10 years, clinical trials and real-world experiences helped clinicians to understand how, when and for how long to u
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Sunitinib treatment"

1

Gafanov, R., T. B. Powles, J. Bedke, et al. "Subsequent therapy following pembrolizumab + axitinib or sunitinib treatment for advanced renal cell carcinoma (RCC) in the phase III KEYNOTE-426 study." Thesis, Elsevier, 2021. https://essuir.sumdu.edu.ua/handle/123456789/86179.

Full text
Abstract:
In the phase III KEYNOTE-426 study, pembrolizumab + axitinib showed significant improvement in OS, PFS, and ORR vs sunitinib in patients with RCC. This analysis assessed subsequent treatment in patients enrolled in KEYNOTE-426.
APA, Harvard, Vancouver, ISO, and other styles
2

Huang, Xiao Hui. "Protective effects of sodium tanshinone II A sulfonate against sunitinib induced cardiotoxicity in H9c2 cell and zebrafish." Thesis, University of Macau, 2014. http://umaclib3.umac.mo/record=b3132193.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Wu, Ting-Yi, and 吳亭儀. "Co-encapsulation of Sunitinib and Doxorubicin to Enhance Drug Resistance Cancer Treatment via Photodynamic therapy/Chemotherapy." Thesis, 2018. http://ndltd.ncl.edu.tw/handle/w98qsu.

Full text
Abstract:
碩士<br>國立臺灣大學<br>醫學工程學研究所<br>106<br>Combination therapy has become a new trend in oncology since its potential to improve treatment response, minimize development of resistance or adverse events. Herein, we report a nanoparticle encapsulate two anti-cancer drugs to achieve synergic therapeutic efficiency of photodynamic therapy and chemotherapy through two-photon laser. Due to its high bio-compatibility and excellent bio-degeadability, mPEG-PCL was utilized as drug delivery vehicle material. Doxorubicin (DOX) and sunitinib (sutent) were both encapsulated in empty mPEG-PCL micelles as sutent/DOX
APA, Harvard, Vancouver, ISO, and other styles
4

Liu, Shu-Yu, and 劉書瑜. "Imbalance of Hypoxia-Inducible Factors Involved in the Drug Resistance of Sunitinib treatment in Renal Cell Carcinoma." Thesis, 2012. http://ndltd.ncl.edu.tw/handle/77745891344857014723.

Full text
Abstract:
碩士<br>國防醫學院<br>生物及解剖學研究所<br>100<br>Renal cell carcinoma (RCC) is an angiogenesis-dependent disease and highly resistant to chemo- and radiation therapies. Therefore, anti-angiogenesis therapy has emerged as a pivotal treatment of metastatic RCC. Tyrosine kinases are important cellular signaling proteins that have a variety of biological activities including cell proliferation, migration and angiogenesis. Multiple kinases are involved in angiogenesis, including receptor tyrosine kinases such as the vascular endothelial growth factor receptor (VEGFR), platelet derived growth factor (PDGFR), etc.
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Sunitinib treatment"

1

Wong, Han Hsi, Basma Greef, and Tim Eisen. Treatment of metastatic renal cancer. Edited by James W. F. Catto. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199659579.003.0089.

Full text
Abstract:
Metastatic renal cancer is resistant to standard chemotherapy. Although some patients with indolent disease can be initially managed with observation, the majority of patients will require aggressive treatment soon after diagnosis. Options include cytoreductive nephrectomy, resection of a solitary metastasis in highly selected cases, or systemic therapy options. The TKIs sunitinib and pazopanib are currently the first-line treatments of choice. Whilst axitinib and cabozantinib have important roles in the second line the PD-1 checkpoint inhibitor, nivolumab, is now established as standard secon
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Sunitinib treatment"

1

Imbulgoda, Amal, Daniel Y. C. Heng, and Christian Kollmannsberger. "Sunitinib in the Treatment of Advanced Solid Tumors." In Recent Results in Cancer Research. Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/978-3-642-54490-3_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Delbaldo, Catherine, Camelia Colichi, Marie-Paule Sablin, et al. "Discovery of Sunitinib as a Multitarget Treatment of Cancer." In Polypharmacology in Drug Discovery. John Wiley & Sons, Inc., 2012. http://dx.doi.org/10.1002/9781118098141.ch16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Bart, Neyns. "Sunitinib for the Treatment of Central Nervous System Glioma." In Controversies in Neuro-Oncology (Avastin and Malignant Gliomas). BENTHAM SCIENCE PUBLISHERS, 2012. http://dx.doi.org/10.2174/978160805132811001010152.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Pasqualetti, Giuseppe, Sergio Ricci, Valeria Calsolaro, Sara Tognini, Antonio Polini, and Fabio Monzani. "The Emerging Role of Sunitinib in the Treatment of Advanced Epithelial Thyroid Cancer." In Recent Advances in Medicinal Chemistry. BENTHAM SCIENCE PUBLISHERS, 2015. http://dx.doi.org/10.2174/9781681081717115020008.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Sunitinib treatment"

1

Kubacka, Urszula, Wouter B. Nagengast, Roeliene C. Kruizinga, et al. "Abstract 380: Sunitinib treatment induces up-regulation of CXCR4." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-380.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Rovithi, Maria, Richard R. de Haas, Richard J. Honeywell, et al. "Abstract 2989: High-dose, intermittent sunitinib as an alternative treatment strategy." In Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-2989.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

McMullen, Calum J., Rachel A. Wood, Margaret R. Cunningham, and Susan Currie. "P5 Assessment of adult rat cardiac fibroblast viability following chronic sunitinib treatment." In The Scottish Cardiovascular Forum 2019, Saturday 2nd February 2019, The Centre for Health Science, Old Perth Road, Inverness, Scotland. BMJ Publishing Group Ltd and British Cardiovascular Society, 2019. http://dx.doi.org/10.1136/heartjnl-2019-scf.13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Mastri, Michalis, Amanda Tracz, Li Shen, Roberto Pili, and John M. L. Ebos. "Abstract 4127: Bolus high-dose neoadjuvant sunitinib treatment overcomes potential for rebound growth during pre-surgical treatment breaks." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-4127.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Ziouti, Fani, Panagiota Touplikioti, Maria-Ekaterini Kontovini, Christina Vadeka, Loukas Kontovinis, and Konstantinos Papazisis. "Abstract 4260: Sunitinib treatment induces Notch expression and activation in renal carcinoma cell lines." In Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-4260.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Qi, Xiaoqiang, Guangfu Li, Dai Liu, Kevin F Staveley-O’Carroll, and Eric Kimchi. "Abstract 5188: Combination of radiofrequency ablation and Sunitinib in the treatment of experimental hepatocellular cancer." In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-5188.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

McBride, Domenica, Abdulfattah Alhazmi, Sarunya Laovitthayanggoon, Marie Boyd, and Susan Currie. "6 Parallel assessment of cell viability in cardiac and cancer cells following treatment with sunitinib." In The Scottish Cardiovascular Forum 2018, 3rd February 2018, Trinity Biomedical Science Institute, Trinity College Dublin Ireland. BMJ Publishing Group Ltd and British Cardiovascular Society, 2018. http://dx.doi.org/10.1136/heartjnl-2018-scf.16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Gaustad, Jon-Vidar, Trude G. Simonsen, Lise Mari K. Andersen, and Einar K. Rofstad. "Abstract B14: The effect of sunitinib treatment in human melanoma xenografts: Associations with angiogenic profiles." In Abstracts: AACR Special Conference: Engineering and Physical Sciences in Oncology; June 25-28, 2016; Boston, MA. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.epso16-b14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

O’Farrell, Alice C., Adam Lafferty, Ian Miller, et al. "Abstract 3010: Proteomic analysis of off-target toxicities following treatment with the tyrosine kinase inhibitor sunitinib." In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-3010.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Sato, Hiromi, Tatsuro Kashiba, Miaki Uzu, et al. "Abstract 5375: Combined treatment of trichostatin A enhances cytotoxic effects of sunitinib on renal cell carcinoma cells." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-5375.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Sunitinib treatment' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography